OR WAIT null SECS
March 08, 2019
Iksuda Therapeutics and Femtogenix, have signed a license agreement aimed at progressing Iksuda’s lead ADC to clinic, with the aim of targeting difficult-to-treat solid tumors.
March 02, 2019
New technologies in the digital factory enhance quality, efficiency, and flexibility for bio/pharmaceutical manufacturing.
While allogeneic therapies can use existing regulatory and quality frameworks, autologous treatments will require pharma’s adoption of true just-in-time and right-first-time concepts, says consultant James Blackwell.
February 25, 2019
The $21.4-billion acquisition will create stand-alone business within Danaher’s life-sciences portfolio.
February 21, 2019
Mustang intends to combine an oncolytic virus with an interleukin-13 Rα2-(IL13Rα2)-specific chimeric antigen receptor to potentially enhance efficacy in treating glioblastoma multiforme.
Teva will apply Insilico’s technology for predictive biomanufacturing to create more efficient biomanufacturing processes.
February 20, 2019
Suppliers address complex supply chains for global biopharmaceutical manufacturing using disposable components.
The company will invest an additional $60 million to expand its manufacturing facility in Durham County, NC.
February 19, 2019
Ireland’s National Institute for Bioprocessing Research and Training received funding from the Science Foundation Ireland’s Technology Innovation Development Award program for monoclonal antibody research.
February 08, 2019
The companies will jointly develop and commercialize an investigational bifunctional fusion protein immunotherapy currently in clinical development for cancer treatment.